Daniel J. Levangie - Mar 1, 2024 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Role
Director
Signature
/s/ Daniel J. Levangie by Mark R. Busch, attorney-in-fact
Stock symbol
EXAS
Transactions as of
Mar 1, 2024
Transactions value $
-$287,500
Form type
4
Date filed
3/4/2024, 08:42 PM
Previous filing
Nov 22, 2023
Next filing
Dec 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXAS Common Stock Sale -$288K -5K -17.87% $57.50 23K Mar 1, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2023.